{"id":1382,"date":"2025-03-03T12:55:00","date_gmt":"2025-03-03T12:55:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=1382"},"modified":"2025-03-03T12:59:18","modified_gmt":"2025-03-03T12:59:18","slug":"previous-studies","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/previous-studies\/","title":{"rendered":"Previous Studies"},"content":{"rendered":"\n
\n

Below are some of the studies that the NRS Neuroprogressive Disease and Dementia Network have been involved in<\/h3>\n\n\n\n
\n
\n
\n

CHIEF-PD<\/h2>\n\n\n\n

The UK’s largest study using cholinesterase inhibitors to reduce falls in Parkinson’s patients.<\/p>\n\n\n\n

\n
Find out more<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

Exenatide-PD3<\/h2>\n\n\n\n

Investigating Exenatide’s potential disease-modifying effects in Parkinson\u2019s Disease.<\/p>\n\n\n\n

\n
Find out more<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n

INSIGHT<\/h2>\n\n\n\n

Measuring insight into memory and thinking abilities in people with dementia.
<\/p>\n\n\n\n

\n
Find out more<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n

PD-COMM<\/h2>\n\n\n\n

The UK’s largest study investigating Speech and Language therapy for Parkinson’s.<\/p>\n\n\n\n

\n
Find out more<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
<\/div>
<\/div><\/div>
\n
\n
\n
\n

CONTACT INFORMATION<\/strong><\/p>\n\n\n\n

Neuroprogressive & Dementia Research Network Office

Old Pharmacy Building
Western General Hospital
Edinburgh
EH4 2XU<\/p>\n\n\n\n

Email: loth.sdcrn@nhs.scot<\/a><\/p>\n\n\n\n

Telephone: 0131 537 3804<\/strong><\/p>\n<\/div>\n\n\n\n

\n

ABOUT US<\/strong><\/p>\n\n\n\n

The NRS Neuroprogressive Disease and Dementia Network team in NHS Lothian conduct commercial and investigator led studies for: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Motor Neurone Disease, dementia with Lewy bodies, Progressive Supranuclear Palsy and Multiple System Atrophy.<\/p>\n\n\n\n

<\/a><\/p>\n\n\n\n

\u00a9 NHS LOTHIAN | YOUR SERVICE.<\/strong><\/sub><\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div><\/div><\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Below are some of the studies that the NRS Neuroprogressive Disease and Dementia Network have been involved in CHIEF-PD The UK’s largest study using cholinesterase inhibitors to reduce falls in Parkinson’s patients. Exenatide-PD3 Investigating Exenatide’s potential disease-modifying effects in Parkinson’s Disease. INSIGHT Measuring insight into memory and thinking abilities in people with dementia. PD-COMM The<\/p>\n","protected":false},"author":382,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[],"class_list":["post-1382","page","type-page","status-publish","hentry"],"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"marianmontanha","author_link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/author\/marianmontanha\/"},"rttpg_comment":0,"rttpg_category":false,"rttpg_excerpt":"Below are some of the studies that the NRS Neuroprogressive Disease and Dementia Network have been involved in CHIEF-PD The UK’s largest study using cholinesterase inhibitors to reduce falls in Parkinson’s patients. Exenatide-PD3 Investigating Exenatide’s potential disease-modifying effects in Parkinson’s Disease. INSIGHT Measuring insight into memory and thinking abilities in people with dementia. PD-COMM The","_links":{"self":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/1382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/users\/382"}],"replies":[{"embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/comments?post=1382"}],"version-history":[{"count":5,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/1382\/revisions"}],"predecessor-version":[{"id":1768,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/pages\/1382\/revisions\/1768"}],"wp:attachment":[{"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/media?parent=1382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/wp-json\/wp\/v2\/categories?post=1382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}